Physician profile
Ivette Perez
NPI 1093298226
$3,038.14
in general payments reported to CMS, 2019-2025
34 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $660 · 2023: $1,061 · 2024: $794 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.66 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.63 | 2022-2024 | |
| Lilly USA, LLC | $301.09 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $248.11 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $227.81 | 2025 | Biktarvy, Epclusa |
| Bayer Healthcare Pharmaceuticals INC. | $197.36 | 2022-2024 | |
| Astellas Pharma US INC | $186.66 | 2022-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $183.16 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Almatica Pharma LLC | $143.94 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Amgen INC. | $130.86 | 2022-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $114.89 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $96.44 | 2022-2023 | Farxiga, Breztri, Evusheld |
| Otsuka America Pharmaceutical, INC. | $72.76 | 2023 | Rexulti |
| Radius Health, INC. | $66.71 | 2022-2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $53.05 | 2021-2024 | Xarelto |
| Hologic Sales and Service, LLC | $40.77 | 2024 | Aptima |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.94 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.77 | 2023-2024 | Synjardy, Jardiance, Glyxambi |
| Alvogen INC | $31.05 | 2024 | Teriparatide |
| Sumitomo Pharma America, INC. | $28.77 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $28.20 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.72 | 2022 | |
| Esperion Therapeutics, INC. | $24.03 | 2023 | Nexletol |
| Nevro Corp. | $24.01 | 2022 | |
| Ardelyx, INC. | $23.98 | 2024 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $23.63 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.88 | 2023 | Keveyis |
| Agios Pharmaceuticals, INC. | $22.50 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $21.36 | 2022 | |
| Sanofi Pasteur INC. | $20.95 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $19.99 | 2021 | |
| Ibsa Pharma INC. | $19.94 | 2022 | |
| Phadia US INC. | $19.32 | 2023 | Immunocap |
| Currax Pharmaceuticals LLC | $17.74 | 2022 | |
| Genentech USA, INC. | $3.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivette Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.